Oncotelic Therapeutics (OTLC) Action Cours

Oncotelic Therapeutics Inc is a biopharmaceutical company based in Agoura Hills, California, operating within the Health Care sector and the Biotechnology industry. The company has 22 employees and went public on August 26, 1993, with the ticker OTLC and ISIN US6283411097. Oncotelic focuses on developing anti-vascular therapeutics for cancer patients and those with sight-threatening eye diseases. Its pipeline includes OT-101, CA4P, and Oxi4503. OT-101 is described as an antisense therapy targeting TGF-2 for solid tumors, with applications in adult brain cancer and pediatric diffuse intrinsic pontine glioma (DIPG). The company also mentions OT-101 as targeting various viruses including SARS and COVID-19, though this appears inconsistent with its primary focus. CA4P is a vascular disrupting agent used in combination with Ipilimumab for solid tumors, particularly melanoma in adults and children. Oxi4503 is a vascular disrupting agent for liquid tumors, with a focus on childhood leukemia. The company's website is www.oncotelic.com. Oncotelic operates as a biotechnology firm with a specialized approach to oncology and ophthalmic conditions, though details on its current development status or regulatory approvals are not provided in the available information.